PBA
ACRV icon

Paradigm Biocapital Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-659,724
Closed -$3.83M – 34
2024
Q2 		$3.83M Buy
+659,724
New +$5.31M 0.15% 34

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paradigm Biocapital Advisors's ACRV Position: Q3 2024 in Review

Paradigm Biocapital Advisors sold out of Acrivon Therapeutics (ACRV) in Q3 2024, closing a stake of 659,724 shares — an estimated $3.83M sold.

Paradigm Biocapital Advisors first reported a position in ACRV in Q2 2024 and held it in 1 quarter. The position peaked at $3.83M in Q2 2024. 55 funds tracked by Wall St. Rank hold ACRV as of Q3 2024.

  • Paradigm Biocapital Advisors reported no remaining Acrivon Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 659,724 Acrivon Therapeutics shares in Q3 2024, an estimated $3.83M.
  • Paradigm Biocapital Advisors first reported a position in Acrivon Therapeutics in Q2 2024 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's Acrivon Therapeutics position peaked at $3.83M in Q2 2024.
  • 55 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.